

28 April 2026

ASX ANNOUNCEMENT

IMEXHS launches agentic AI platform for radiology

Five proprietary AI agents now embedded across the full Aquila+ workflow

Highlights

- IMEXHS has launched an AI-native, agentic platform for radiology - five proprietary AI agents embedded directly into Aquila+, automating the radiology workflow from scheduling through to final report delivery.
- Two agents are already live across the Company's client base, one is in final testing, and two are in active development - ahead of schedule.
- Aquila+, the Company's next-generation RIS/PACS platform, is commercially live and operating at eight sites.

IMEXHS Limited (ASX: IME) ("**IMEXHS**" or "**the Company**") is pleased to announce the launch of its agentic AI platform for radiology — a full-workflow suite of five proprietary AI agents now embedded across Aquila+, the Company's next-generation RIS/PACS platform.

IMEXHS CEO Dr. German Arango commented, "Three years ago, at the Bogotá Radiology Society, I reached for a childhood memory - *The Jetsons* - to illustrate where I believed medicine was heading. In that cartoon, a patient would step into a capsule and emerge with a diagnosis and a treatment plan. Behind the image lies a serious idea: more and more tasks will be carried out by systems, and human beings will need to adapt. Far from making doctors redundant, that shift would give them more time with their patients.

Today's announcement is the concrete expression of that thesis. We are no longer describing what is coming. We are announcing what we have built: five proprietary AI agents, embedded across Aquila+, automating the radiology workflow from scheduling through to final report delivery - so that the people in our clients organisations can do the work that only humans can do."

Why now: an industry under exponential pressure

Demand for diagnostic imaging is rising at an accelerating rate while the radiologist workforce cannot keep pace. In this environment, the operational bottlenecks around the radiologist - scheduling, triage, distribution, monitoring - are where delay, error and cost concentrate. The prevailing industry response has been to layer single-point AI tools onto legacy workflows, producing incremental rather than structural change.

IMEXHS's approach is different. Rather than add AI to a single report or to a specific imaging modality, the Company has built a system of AI agents that operate in the background of the workflow itself, resolving

operational tasks autonomously so that radiologists can focus on image interpretation and clinical decision-making. This is what it means to be AI-native.

The five agents

Agent 1 - Intelligent Appointment Scheduling (in active development) Reads medical orders and insurance authorisations, applies each institution's scheduling rules, and books patient appointments automatically. Operational modelling projects a reduction in call-centre staffing requirements of up to 80% and a reduction in patient wait times of 50 – 60%.

Agent 2 - Intelligent Study Prioritisation (final testing) Analyses clinical data and assigns study priority using a self-learning medical dictionary that continuously adapts to new clinical terminology. Critical cases surface immediately for faster radiologist review - reducing critical study delays and medico-legal exposure for clients.

Agent 3 - Intelligent Auto-Distribution (live across client base) Evaluates each radiologist's workload in real time - reading speed, pending cases and clinical priorities - and dynamically assigns and reassigns studies to optimise performance. Balances caseloads platform-wide, prevents queue build-up and improves SLA compliance.

Agent 4 - Study Non-Attendance Alerts (live across all clients) Monitors every study in the reading queue in real time and flags any case at risk of exceeding its priority-based SLA threshold. Delivers platform-wide visibility of at-risk studies, reduces overlooked cases, and creates a natural adoption pathway into the Auto-Distribution agent - generating cross-sell optionality within the existing client base.

Agent 5 - RV Mentor (partially live; in active development) An AI co-pilot for the radiologist at the point of reading, available exclusively on Aquila+. Live capabilities today include contextual medical queries, report content evaluation and quality checks, image analysis support and academic literature search. The near-term roadmap adds native workspace integration, automatic pre-report generation by study type, auto-correction and translation of reports, and study-to-report correlation validation.

The strategic picture

All five agents are proprietary IMEXHS intellectual property, developed and owned by the Company. Collectively, they deliver operational efficiency by automating work that currently requires human operators at scale; clinical safety through reduced SLA breach and medico-legal risk for clients; medical productivity by increasing radiologist output without proportional headcount growth; and scalable unit economics that allow volume to grow without proportional cost growth.

The agentic architecture creates a structural moat. Each additional agent deepens client dependency on the Aquila+ platform, lifts switching costs, and opens new cross-sell pathways inside the existing customer base.

Dr Germán Arango, Co-Founder and CEO, added: "The defining story of the quarter is product. Our entire strategy has pivoted towards an AI-native, agentic platform for radiological workflow management - and execution against that vision is well ahead of schedule. This is a new chapter for the Company and, we believe, for the industry."

A video showing the agents functionality will be released on the <https://imexhs.com/en/> website and shared with prospective clients.

Authorised for release by the Board of IMEXHS Limited.

-ENDS

For more information, please contact:

Business Inquiries

Reena Minhas, CFO & Company Secretary

E: enquiries@imexhs.com.au

T: +61 (0)438 481 139

About IMEXHS

IMEXHS Limited (ASX: IME) is an innovative provider of medical imaging software and radiology services in 18 countries including Colombia, the US and Australia. Founded in 2012, IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are completely cloud-based, vendor neutral and zero footprint, with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that enhances patient outcomes. For more information, [visit www.imexhs.com](http://www.imexhs.com)